change control luisa stoppa manufacture of sterile medicines – advanced workshop for sfda gmp...
TRANSCRIPT
Change Control
Luisa Stoppa
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectors
Nanjing, the People’s Republic of China – 16-20 November 2009
2 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Objectives of the presentationObjectives of the presentation
To answer to the following questions:
What is the purpose of change control?
What must be taken into consideration when introducing change control programs?
How can changes be graded?
What should be regulated in a “change control” operating instruction?
What is the function of the change control committee?
How shall the implementation of changes be recorded?
What has an inspector to inspect and to check?
3 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
ProgrammeProgramme
To introduce the general elements on change control
To train you in the guidelines (WHO-GMP, PIC/S guidelines, EU-GMP)
To become confident with SOP, forms and records of Change Control System
To develop your inspection plan on change control
4 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Principles of change controlPrinciples of change control
Before a medicinal product can be released, we need:
the manufacture and quality control procedure should be documented in the form of instructions;
The materials to be used must be specified;
The basic conditions required for a reproducible quality, efficacy and safety must be defined (i.e. suitable rooms, qualified facilities, trained personnel, validated procedures, established specifications)
5 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Principles of change controlPrinciples of change control
Before the requirements can be implemented, the suitability of equipments/facilities and procedures must be proven with qualification / validation
This principle is not only valid the first time a medicinal product is manufactured or the first time a facility is used or a procedure comes into effect
The principle applies to the whole history of a medicinal product, a procedure or a facility and it is to be guaranteed
As each requirement is stated in a document, it is clear that each change control for the requirements must also always involve a documentation control
6 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Principles of change controlPrinciples of change control
Each change to previously approved requirements requires a review and authorization to keep the system in its original state of “proven suitability”
Formal change control guarantees that all changes are evaluated for their effect on product quality or validation status
Change control minimizes the risk that changes can have on the quality or process characteristics
Change control programs have become recognized as essential element of the pharmaceutical quality assurance system
The task of
change control
7 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Principles of change controlPrinciples of change control
In the WHO-GMP guideline glossary there is definition of the term “change control”
However, the GMP guideline basically contains only few notes about the handling of changes
8 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Principles of change controlPrinciples of change control
In the American Code of Federal Regulation CFR, the responsibility for the verification and authorization of changes is task of the quality control unit
In the EU regulations, the responsibility is assigned to Quality Unit
As the change control is considered an essential element of the pharmaceutical quality assurance system, it is logical the person responsible is quality assurance (QA representative, QA head)
9 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Principles of change controlPrinciples of change control
Change control is not department-specific, rather the task of the whole company
The change control monitors all types of changes which can influence the process or product quality and states the measures necessary for implementing the change or decides that a change should not be implemented
10 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
records / forms and other relevant documents
standard operating procedure / instructions
QM statement
change requests and other relevant documents
operating instructionfor change control
changepolicy
Change control programsChange control programs
Change control program is a managerial task
We expect a quality structure of change control
11 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control programsChange control programs
Many types of changes affect several areas at the same time:
GMP requirements Regulatory requirements
Process security (validation)
Product quality (specifications, approval)
Effectiveness / safety (approval)
Suitable rooms and equipment (qualification)
Suitable personnel (training, experience)
12 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
A central processing of change procedures, coordinated by the quality assurance department, has several advantages:
– there is a common understanding of what a change represents;– the classification schemes used by the staff involved to rate
changes are congruent;– the risk connected with the change can be evaluated in a multi-
disciplinary manner;– there is uniform documentation and authorization procedure
Change control programsChange control programs
13 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
The type and scope of a change control program must comply with the requirements:
1. In the classical GMP-relevant areas the change control helps to maintain the validated and established status. Validated processes, qualified facilities, material specifications can be influenced by changes and medicinal products no longer comply with specifications
Change control programsChange control programs
14 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
2. Holder of marketing authorization must guarantee that necessary regulatory pre-requisites are met. Contract manufacturers that do not have their own authorization must guarantee that the contract giver is informed of internal changes that could have an influence on their application documentation (this requires that the contract giver is included in the change control program of the contract manufacturer)
Change control programsChange control programs
15 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
3. In areas where medicinal products are developed, processes are optimized or clinical research takes place, changes should also evaluated and documented so that the development of medicinal product or process must be consistently proved
Change control programsChange control programs
16 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control programsChange control programs
Many companies rate the changes requiring control
EU-GMP
17 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control programsChange control programs
The example is one way to rate them:
Major changeMinor changeNot requiring control
Significance of change
Influences product quality or process reliability
Influences a unit requiring control
No relevance to GMP or authorization
Possible measures (selection)
Official license
New approval
revalidation
Amendment
Review
documentation
No relevance to GMP or authorization
examplesChange of manufacturer: other synthesis route of a starting material (other impurities)
Removal of processes to another site
Change in the product composition
Change to the process parameters
Replacement of apparatus part of the same design
Change of cleaning agent for floors
Change of laundry for work clothes (non-sterile or antibiotics area)
Change to working times
Installation of air conditioner in administrative area
Change in purchase procedure
18 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control programsChange control programs
Other classifications are possible
19 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
It is not decisive which and how many change-classes a company has rated, but how it is guaranteed that changes requiring control are recognized as such and implemented according to a defined procedure
Change control programsChange control programs
20 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Not all changes require a revalidation
Change control programsChange control programs
WHO-GMP
21 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
In the PIC/S document PI 006 (chapter 6.7.4) there is a list of changes that may require a re-validation:
Change control programsChange control programs
22 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Also in the WHO-GMP guidelines there is a list of changes that may require a re-validation
Change control programsChange control programs
23 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
WHO-GMP guidelines
Change control programsChange control programs
24 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
PIC/S document PI006
Change control programsChange control programs
25 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
The so called “trials” cause a problem in change control program.
Trials are preliminary, temporary changes which can permanently established or revoked after a trial period
With trials, there is a risk that these intended temporary changes gradually become permanent changes without a formal change control procedure being carried out
How long a trial is retained and whether it is withdrawn after a trial phase or be introduce permanently, should be included in the same procedure “change control” as all other changes
Change control programsChange control programs
26 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
“Deviations” should not be treated as changes, not even when deviations become changes after a failure has been clarified
Deviation is an unplanned and undesirable deviation from a requirement; it occurs spontaneously
Deviations should be dealt with according a procedure about “handling deviations”
All variations implemented in emergency (no planned, no controlled, no permanent) are included in deviations
Change control programsChange control programs
27 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Changes )planned changes(
Deviations )unplanned changes(
Submission of request -description of change
-rationaleEvaluation
-effect on validation status -definition of revalidation measures
ApprovalImplementation of changeClosing
Notification -description of deviation
Evaluation -effect on product quality
-definition of corrective actions -effect on validation status
-definition of revalidation measures
Implementation of deviationClosing
Change control programsChange control programs
28 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
An important function as part of the change control program is fulfilled by the “change control committee CCC” (also known as change control team or change control board)
This committee consists of the head of Quality assurance, the heads of manufacturing, quality control, regulatory affairs, IT department, engineering, sales
The task of the committee is to evaluate the changes, establish and coordinate measures to put in place and authorize the changes
Change control programsChange control programs
29 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control programsChange control programs
PIC/S guideline
30 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
A problem is the issue of which changes the change control team should dealt with
It is obvious that this team cannot deal with all changes in the company
As matter of fact, only changes requiring control should be processed by this team
Change control programsChange control programs
31 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Firstly, these are changes relevant for the regulatory status
Secondly, they are changes which could have an influences on the attributes of a GMP-relevant system, facility, equipment, material/product, procedure/process
The team should also deal with all changes whose grade or implementation is unclear or questionable
Change control programsChange control programs
32 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
How the team members communicate with each other?
Not all changes require a meeting
In cases which are easy to make a decision about, it can be useful traditional paper-based circulation procedures, e-mail agreement or access to Intranet-based forms
Change control programsChange control programs
33 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
When a change control program has been introduced, the effectiveness of the system can be reviewed using data which is easy to determine
Total number of changes request /year
Number of completed change requests / year
Change type / department involved
Duration of procedure: from application to closing
Number of deviations/year
Number of internal or external complaints /year
Number of OOS /year
Change control programsChange control programs
34 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control programsChange control programs
EU-GMP
35 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control requires a written procedure to establish at least the following steps:
What type of changes does change control take into account?What are the requirements for urgent changes?For which areas does this operating procedure apply?Who can suggest changes?How are changes requested (forms, method of communication)?How are changes graded and who is responsible for the rating?How are the measures for carrying out the change established?Who is responsible for the implementation and monitoring of all measures?Who is included in the change control team?What are the duties of the change control team?How is the change documented (format, content, storage)?Who is responsible to authorize changes?
DocumentationDocumentation
36 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
DocumentationDocumentation
Change control requires a written procedure to establish at least the following steps:
37 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
DocumentationDocumentation
Change control requires a written procedure to establish at least the following steps:
38 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
All quality-relevant changes should be documented
All actions to be taken, including the need for and extent of qualification or validation, should be described
The records can be archived in paper form or electronically
When storing documents, raw data and other relevant documents for change should be kept accessible
DocumentationDocumentation
39 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Changes requiring control are generally documented in the form of a “change request” in which the applicant for the change proposes the type of change, suggests the timeframes and measures for carrying out the change
The change control team authorizes or not the change
The documentation for the change procedure should show that the change was evaluated (risk analysis)
DocumentationDocumentation
40 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
DocumentationDocumentation
WHO-GMP
41 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control procedure (example 1)
DocumentationDocumentation
42 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control procedure (example 2, 1/2)
DocumentationDocumentation
43 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control procedure (example 2, 2/2)
DocumentationDocumentation
44 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control procedure includes flow chart of the change control process and the change request form (or change form)
Change request form records a request for change so that each change is documented before it is approved
The change request form includes the description of the change, the benefits, costs, urgency of the change, change impact
DocumentationDocumentation
45 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control procedure: flow chart (example 1)
DocumentationDocumentation
46 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
DocumentationDocumentation
Change control procedure: flow chart (example 2)Change Request
Submission
Evaluation ofChange Impact
Validation Change Request
More information
required
Change Activities
Change Closed
Approval
Activities Completion
Change Activities
Approval
Activities Completion
47 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
DocumentationDocumentation
Change control procedure: flow chart (example 3)
48 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change control procedure: flow chart (example 4)
DocumentationDocumentation
CCB = change control board
49 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
DocumentationDocumentation
Change control procedure: flow chart for change master documents (example 1)
50 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change request form (example 1, 1/2)
DocumentationDocumentation
51 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change request form (example 1, 2/2)
DocumentationDocumentation
52 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change request form (example 2, 1/2)
DocumentationDocumentation
53 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change request form (example 2, 2/2)
DocumentationDocumentation
54 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Change request form (example 3)
DocumentationDocumentation
55 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
DocumentationDocumentation
Change database: electronic copy
56 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
DocumentationDocumentation
Change control logbook
Change control logbook (year:________)
Nb. Request date
Requester / department
ItemDescriptionApproval date
Actions and time limit
Closing date
Page:__ of____
QA Manager signature _________ Date_______
57 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Examples of changesExamples of changes
Changes to the cleaning procedure- use of a new cleaning agent
- change in concentration / volumes of cleaning agent
- change in volumes of rinsing water
- change of cleaning process parameters
Changes to the production equipment- changes to the CIP equipment
- changes to / replacement of equipment parts (difficult to give detailed examples as these changes are too diverse)
- change of process parameters
58 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Examples of changesExamples of changes
Changes to the product
- changes to composition (reformulation with different excipients)
- changes to the manufacturing process (i.e. transfer of a product)
Changes to HVAC system / unidirectional flow
Changes in lay-out (i.e. implementation of a pass-box)
59 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Inspection planInspection plan
To ask for the Change Control standard operating procedure
To check that all relevant steps for change control implementation are detailed
To choose some applications (from the list in the logbook)
To verify the applications and all requested documents (change request form, investigation, request and closing date)
60 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
ConclusionConclusion
The old adage says: the only thing constant is change!
61 |
Manufacture of sterile medicines – Advanced workshop for SFDA GMP inspectorsNanjing, the People’s Republic of China, 16-20 November 2009
Reference documentsReference documents
WHO GMP guidelines – Technical Report series n. 937
EU GMP guidelines, Part I annex 15
ICH Q7A or EU GMP Part II chapter 13
PIC/S Recommendations PI 006-3
62 |Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009